BACKGROUND: Recently, multiple epidemiological studies have linked imatinib with the alteration of renal function in chronic myeloid leukaemia (CML) patients. This meta-analysis aimed to summarize the impact of imatinib use on renal function in CML patients. METHODS: A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature-screening, risk of bias and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria. RESULTS: A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p < .05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (chronic kidney disease or acute kidney injury) was found to be significantly higher in imatinib users as compared to other tyrosine kinase inhibitor (TKI) users with a pooled relative risk of 2.70 (95% CI: 1.49-4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. CONCLUSION: This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Department of Hemato Oncology and BMT Unit Rajiv Gandhi Cancer Institute and Research Centre New Delhi India

Department of Pharmaceutical Medicine School of Pharmaceutical Education and Research Jamia Hamdard New Delhi India

Zobrazit více v PubMed

Williams LA, Ault P, Wang XS, et al. The symptom burden of chronic myelogenous leukemia (CML). ASH Publications; 2008.

Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36:56-59.

Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524-548.

Lin Q, Mao L, Shao L, et al. Global, regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:580759.

Breccia M. Imatinib improved the overall survival of chronic myeloid leukemia patients in low-and middle-income countries: a therapeutic goal has been reached. EClinicalMedicine. 2020;19:100277.

Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.

Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879-894.

Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6:e2014007.

Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised enestnd trial. Lancet Oncol. 2011;12:841-851.

Hino A, Yoshida H, Tada Y, et al. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. Int J Hematol. 2016;104:605-611.

Tong WG, Kantarjian H, O'Brien S, et al. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer. 2010;116:3152-3159.

Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894-3904.

Page MJ, McKenzie JE, Bossuyt PM, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008-2012.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.

Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017;17:684-695.

Marcolino MS, Boersma E, Clementino NCD, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22:2073-2079.

Molica M, Scalzulli E, Colafigli G, et al. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available tkis and correlation with cardiovascular events. Ann Hematol. 2018;97:1803-1808.

Ou Z, Yu D, Liang Y, et al. Analysis of the global burden of disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017. Cancer Commun. 2020;40:598-610.

Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98:1627-1640.

Sakurai M, Kikuchi T, Karigane D, et al. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol. 2019;109:292-298.

Okamoto S, Ureshino H, Kawaguchi A, Miyazono M, Ikeda Y, Kimura S. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int J Hematol. 2020;112:41-45.

Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting treatment with gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther. 2009;34:607-610.

Boor P, Ostendorf T, Floege J. Pdgf and the progression of renal disease. Nephrol Dial Transplant. 2014;29:i45-i54.

Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008;19:12-23.

Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:169-174.

Elshahat S, Cockwell P, Maxwell AP, Griffin M, O'Brien T, O'Neill C. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS One. 2020;15:e0230512.

Ozieh MN, Bishu KG, Dismuke CE, Egede LE. Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011. BMC Health Serv Res. 2017;17:368.

Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the mdrd study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941-1951.

Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the cockcroft-gault, mdrd, and new ckd-epi formulas in relation to gfr, age, and body size. Clin J Am Soc Nephrol. 2010;5:1003-1009.